Utilizing longitudinal bone marrow samples from relapsed-refractory MM patients treated with Elotuzumab-Iberdomide-Dexamethasone (EId), the study aims to evaluate immunologic profiles and specific biomarkers such as IKZF1 in immune cells. The project has three specific aims: 1) to profile the immune system of MM patients before EId treatment to identify correlations with high-risk MM phenotypes, 2) … Continued
To test the hypothesis that plasmacytomas can represent spatial and temporal clonal escape events, featuring distinct myeloma-defining genomic events characteristic of active disease, through the following specific aims: Aim 1. Compare genomic driver events in paired samples from patients with newly diagnosed solitary plasmacytoma (SP) with minimal marrow involvement versus newly diagnosed multiple myeloma (NDMM) … Continued
This project aims to systematically characterize the functional genomics of 17p13 deletion in multiple myeloma (MM). Aim 1 seeks to identify potential tumor suppressor genes (TSGs) within 17p13 that cooperate with TP53 loss, investigating if haploinsufficiency of these genes contributes to MM pathogenesis. Aim 2 aims to define therapeutic vulnerabilities in MM cells with 17p … Continued
This project aims to develop a clinically useful method for monitoring treatment response in multiple myeloma (MM) by detecting circulating tumor cells in peripheral blood (PB) using next-generation flow cytometry. The proposed approach, called BLOOD-FLOW, involves optimizing immunomagnetic enrichment of circulating plasma cells from large PB volumes, achieving a limit of detection two logs more … Continued
The aim of the IMS funded project was to investigate whether different subgroups of patients (i.e. defined by baseline clinical and biological characteristics) with newly-diagnosed multiple myeloma who have achieved a complete response (CR) after autologous stem cell transplantation (ASCT) benefit from different maintenance treatments or if some of them even require observation only. Due … Continued
The study aims to investigate mechanisms of Multiple Myeloma (MM) resistance to Natural Killer (NK) cells and the role of NK cells’ interaction with macrophages in immune evasion. Aim 1 focuses on validating candidate NK cell resistance genes identified from previous functional genomic screens, using CRISPR editing and activation techniques on MM cell lines. This … Continued
This project aims to comprehensively analyze the spatial organization of the plasma cell niche and its alterations in monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) using CO-Detection by IndEXing (CODEX) multiplex tissue imaging. The study anticipates that cellular interactions within the bone marrow microenvironment generate specific tissue features, which can be identified … Continued
Novel genomic approaches may enable better prediction of progression risk to multiple myeloma (MM) from the more indolent precursor stages of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). In support of this, the Ghobrial and Getz laboratories have previously collected, analyzed, and published biomarkers from the tumor cell fraction of SMM … Continued
The project aims to analyze tumor-infiltrating lymphocytes (TILs) in multiple myeloma patients treated with bispecific T-cell engager (bsAb) therapy, utilizing single-cell analyses to understand T-cell diversity, phenotype dynamics, and specificity. By correlating sequencing data with functional validation of anti-tumor reactivity, the study seeks to predict response to bsAb therapy. This integrated approach, combining clinical expertise … Continued
The research plan aims to assess the utility of mass spectrometry (MS) for diagnosing and monitoring patients with multiple myeloma (MM), amyloidosis (AL), and Waldenström’s macroglobulinemia (WM). Specific aims include comparing MS with standard methods like serum protein electrophoresis (SPEP) and immunofixation (IFE) for identifying and quantifying monoclonal proteins, evaluating MS’s ability to detect minimal … Continued
The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.
The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.
